the Voice of
The Communist League of Revolutionary Workers–Internationalist
“The emancipation of the working class will only be achieved by the working class itself.”
— Karl Marx
Feb 14, 2022
The average wholesale price of Xtandi, a very effective drug to treat prostate cancer, is close to $190,000 a year. Because prostate cancer is a disease of older men, Medicare can pick up most of the bill. Still, even Medicare patients fork out up to nearly $10,000 a year for this drug through deductibles and co-pays. This is a very expensive drug, particularly for a patient afflicted with a lethal disease.
Patients living in other countries also pay a very high price for this drug. For example, the healthcare system in Japan pays close to $32,000 a year. But this price is much lower than that of the U.S., indicating that the U.S. price is ridiculously inflated to $160,000 a year.
UCLA, a public university in California, developed this drug. The Federal Government paid for its development. So, the public has already paid for the development of this drug through their taxes.
Now, they have to pay again as Pfizer and Astellas superinflate its price.